RecruitingNot ApplicableNCT06423664

Improving Neurodevelopmental ouTcomes After Prenatal Cannabinoid in uTero Exposure

Pilot Feasibility Trial of Improving Neurodevelopmental ouTcomes After Prenatal Cannabinoid in uTero Exposure (INTACT)


Sponsor

IDeA States Pediatric Clinical Trials Network

Enrollment

20 participants

Start Date

Feb 6, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The INTACT trial is a multisite pilot feasibility study aimed at testing the effectiveness of the INTACT Intervention program in improving neurodevelopmental outcomes in infants prenatally exposed to cannabinoids. The trial will enroll 20 birthing parent/infant dyads across three sites and will evaluate feasibility endpoints rather than clinical outcomes. The study duration is 22 months, including study start-up, enrollment and intervention, and data analysis and manuscript preparation.


Eligibility

Max Age: 7 Days

Inclusion Criteria12

  • Birthing Parent
  • Age of majority, as defined by the state of residency
  • Cannabinoid use during pregnancy confirmed with self-report
  • Have the ability to speak, read, and understand English
  • Birthing parent who delivered at one of the hospitals where study team members have clinical privileges to access medical records
  • Has parental custody of the infant
  • Singleton pregnancy with live birth
  • Has an electronic device capable of watching videos and able to stream/download videos for viewing and permitting video conferencing
  • Has study access to the internet
  • Infant
  • Term infants at birth (>37 weeks' gestation)
  • Biological child of the birthing parent

Exclusion Criteria8

  • Birthing Parent
  • Other illicit drug use, excluding cannabinoids, during pregnancy (such as heroin or cocaine) per self-reported or toxicology results
  • Opiate use (prescribed or unprescribed) per self-report or toxicology results during this pregnancy
  • Prolonged hospitalization following delivery longer than 7 days
  • Infant
  • Has major birth defect(s) including physical anomalies including limb malformations/absence of limbs or chromosomal abnormalities
  • Diagnosed with neonatal encephalopathy, metabolic disorder, stroke, intracranial hemorrhage, or meningitis during birth hospitalization
  • Received any major surgical intervention during the birth hospitalization or required a prolonged birth hospitalization (prolonged hospitalization being any hospitalization longer than 7 days)

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BEHAVIORALPlay and Learn Strategies (PALS) Program

Monthly modules and personalized coaching sessions designed to strengthen maternal responsiveness and sensitivity which, in turn, improves infant social-emotional behavior and development outcomes.


Locations(3)

University of New Mexico Health Sciences Center

Albuquerque, New Mexico, United States

Avera Research Institute

Sioux Falls, South Dakota, United States

University of Vermont Medical Center

Burlington, Vermont, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06423664


Related Trials